Adicet Therapeutics, Inc.

Adicet Bio, Inc.

Andy An-deh Lin

Aya Jakobovits

Orit Foord

Marianne Theresa Santaguida

Radhika Chetan Desai

Daulet Kadyl Satpayev

Yifeng Frank Jing

Yan Li

The present invention relates to engineered γδ T-cell(s) and methods for using the same as a therapeutic with a potent and selective ability to target an antigen of choice. Engineered γδ T-cells of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders. Also disclosed are methods for expanding engineered and non-engineered γδ T-cell(s) populations to therapeutically useful quantities. An engineered γδ T-cell of the disclosure can be a universal donor, and can be administered to a subject with any MHC haplotype.

Engineered γδ T-cells

The present invention relates to methods for the selective expansion of γδ T-cell population(s), compositions and admixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched γδ T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.

Methods for selective expansion of gamma delta t-cell populations and compositions thereof

The present invention relates to methods for the selective expansion of &#x3b3;&#x3b4; T-cell population(s), compositions and admixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched &#x3b3;&#x3b4; T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.

Methods for selective expansion of &#x3b3;&#x3b4; T-cell populations and compositions thereof

The present invention relates to engineered &#x3b3;&#x3b4; T-cell(s) and methods for using the same as a therapeutic with a potent and selective ability to target an antigen of choice. Engineered &#x3b3;&#x3b4; T-cells of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders. Also disclosed are methods for expanding engineered and non-engineered &#x3b3;&#x3b4; T-cell(s) populations to therapeutically useful quantities. An engineered &#x3b3;&#x3b4; T-cell of the disclosure can be a universal donor, and can be administered to a subject with any MHC haplotype.

Growing community of inventors

Palo Alto, CA, United States of America

Andy An-deh Lin